AI-generated research brief — verify at source
MRLN-Sparing Radiotherapy Preserves Survival and Reduces Dysphagia in Nasopharyngeal Carcinoma
At five years of follow-up, medial retropharyngeal lymph node (MRLN) sparing radiotherapy achieved non-inferior local relapse-free survival compared with standard radiotherapy (89.2% vs 90.6%; stratified HR 1.03, 95% CI 0.61–1.74), with virtually identical overall survival (89.2% vs 90.3%; stratified HR 1.06, 95% CI 0.68–1.68). The sparing approach was also associated with a lower rate of swallowing toxicity, supporting its potential adoption as a new standard of care in patients without MRLN involvement.
What Was Studied
This trial investigated whether selectively excluding the medial retropharyngeal lymph node region from the radiotherapy target volume would maintain equivalent oncological control — measured by local relapse-free survival — while reducing treatment-related toxicity, particularly dysphagia, in patients with non-metastatic nasopharyngeal carcinoma who did not have MRLN involvement at diagnosis. The central question was whether prophylactic irradiation of this nodal region is necessary in node-negative patients, or whether its omission could spare critical swallowing structures without sacrificing tumour control.
How It Was Studied
This is a pre-specified five-year analysis of an open-label, non-inferiority, multicentre, randomised phase 3 trial conducted across three Chinese medical centres, with enrolment between November 2017 and December 2018. A total of 568 adults aged 18–65 years with untreated, non-keratinising, non-metastatic nasopharyngeal carcinoma and no radiographic evidence of MRLN involvement were enrolled and randomised 1:1 to either MRLN sparing radiotherapy or standard radiotherapy. Randomisation was stratified by institution and treatment modality, which included radiotherapy alone, concurrent chemoradiotherapy, or induction chemotherapy combined with radiotherapy or concurrent chemoradiotherapy. The primary endpoint was local relapse-free survival, and a non-inferiority margin of 8% was pre-specified. Objective swallowing function was assessed using videofluoroscopic swallowing studies and MRI measurements of pharyngeal constrictor muscles, providing quantitative evidence beyond self-reported outcomes. Median follow-up at the time of this report was 70 months.
What Was Observed
- Five-year local relapse-free survival was nearly identical between groups, at 89.2% in the MRLN sparing arm versus 90.6% in the standard arm — a difference of 1.4 percentage points that falls well within the pre-specified 8% non-inferiority margin. The hazard ratio of 1.03 (95% CI 0.61–1.74; P=0.90) indicates no meaningful difference in the risk of local relapse between the two approaches.
- Overall survival at five years was similarly equivalent, with 89.2% in the MRLN sparing group versus 90.3% in the standard group. The estimated hazard ratio of 1.06 (95% CI 0.68–1.68; P=0.79) confirms no statistically significant or clinically meaningful difference in mortality risk between treatment arms.
- Swallowing toxicity was reduced in the MRLN sparing group, with grade ≥1 dysphagia occurring in 22% of evaluable patients (45 of 206) in the sparing arm. Objective assessments using videofluoroscopy and MRI of pharyngeal constrictor muscles supported the conclusion that reduced radiation dose to these structures translated into a measurable functional benefit.
Why This Matters
Dysphagia is a recognised and functionally significant complication of radiotherapy for nasopharyngeal carcinoma, arising from radiation-induced damage to the pharyngeal constrictor muscles, which lie adjacent to the MRLN region. This trial demonstrates that deliberately excluding this nodal region from the treatment volume does not compromise tumour control or survival at five years, while producing a lower burden of swallowing dysfunction — an outcome with direct implications for patients’ long-term quality of life. The authors conclude that this volume modification warrants consideration as a revised standard of care for patients presenting without MRLN involvement.
How to Read This Result
This is a well-designed, adequately powered phase 3 randomised trial with nearly six years of median follow-up, and the non-inferiority conclusion is robust within the pre-specified margin; however, the open-label design may introduce assessment bias in patient-reported outcomes, and the full between-group comparison of dysphagia rates is not completely reported in the abstract, which limits precise quantification of the swallowing benefit.
Limitations
The abstract does not explicitly report study limitations.